William Blair analysts Tim Lugo, Lachlan Hanbury-Brown, and John Boyle observe that although the confirmatory data for Filspari demonstrate a distinct advantage for patients, reinforcing the case for its ongoing marketing, these findings may offer limited motivation for payers to prefer Filspari over irbesartan. Additionally, there remains uncertainty regarding the market potential for Filspari in IgAN.

Although Filspari holds the distinction of being the inaugural nonimmunosuppressive therapy approved for IgAN, and while the data indicate a tendency favoring Filspari when compared to irbesartan, William Blair shows reservations concerning the clinical significance of the narrow and statistically insignificant improvement over irbesartan. 

While these findings do introduce regulatory considerations for Filspari, the data do not provide adequate grounds for the FDA to contemplate removing the product from the market, the analysts write.

The analysts say the trajectory of Filspari will be the primary catalyst influencing stock performance in the short term, including the early launch in IgAN and forthcoming updates arising from regulatory dialogues regarding a potential course of action in FSGS. 

Concurrently, they recognize the potential of pegtibatinase as a promising asset within the pipeline.

Price Action: TVTX shares are down 41.03 at $7.59 on the last check Thursday.